US Food and Drug Administration Facilitated Pediatric Approval Programs: Application to Pediatric Neurological Disorders

Abstract

Crucial time is often lost while waiting for approval of therapies for pediatric neurological disorders, many of which have aggressive manifestations with devastating effects. There are logistical, ethical, and financial impediments that face the studies needed to determine efficacy and safety of therapies in children. In this article, the authors present the Food and Drug Administration’s programs aimed at facilitating the development of pediatric drugs, focusing on their application to pediatric neurological disorders. They also provide examples of drugs that received, or are currently enrolled in, these programs. Reflecting upon the commonalities of drugs receiving these designations, the authors highlight underlying ethical issues related to pediatric drug development and emphasize the need for structured incentives to stimulate approval and production of drug therapies for pediatric neurology patients. By consolidating information that applies to drug approval of pediatric neurological disorders, stakeholders in drug development can enhance treatment development for these disorders.

Keywords

drug approval pediatric drugs FDA rare pediatric drug designation pediatric research equity act Best Pharmaceuticals for Children Act

Get full access to this article

View all access options for this article.

References

Center for Drug Evaluation and Research. Pediatric information incorporated into human prescription drug and biological products labeling good review practice. March 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-information-incorporated-human-prescription-drug-and-biological-products-labeling-good.

Kipnis

. Seven vulnerabilities in the pediatric research subject. Theor Med Bioeth. 2003;24(2):107–120. doi:10.1023/a:1024646912928.

Protection of Human Subjects, HHS. 45 C.F.R. Part 46, Subpart D; Protection of Human Subjects, FDA. 21 C.F.R. Part 50, Subpart D.

Owen

. Clinical Discussion of Specific Populations. FDA’s Clinical Investigation Course. https://www.fda.gov/media/84964/download.

Ollivier

Mulugeta

Ruggieri

Saint-Raymond

Yao

Paediatric extrapolation: A necessary paradigm shift. Br J Clin Pharmacol. 2019;85(4):675–679. doi:10.1111/bcp.13809.

Madabushi

Cox

Hossain

, et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol. 2011;51(1):19–28. doi:10.1177/0091270010365550.

FDA. Pediatric information incorporated into human prescription drug and biological product labeling guidance for industry. FDA; March 2019. https://www.fda.gov/media/84949/download.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205836Orig1s000,205837Orig1s000,205838Orig1s000lbl.pdf.

Berger

Choi

Kaminski

, et al. Importance and hurdles to drug discovery for neurological disease. Ann Neurol. 2013;74:441–446. https://doi.org/10.1002/ana.23997.

10.

Center for Drug Evaluation and Research. Drug Research and Children. US Food and Drug Administration. May 4, 2016. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/drug-research-and-children.

11.

Pellock

Carman

Thyagarajan

Daniels

Morris

D’Cruz

. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology. 2012;79(14):1482–1489. doi:10.1212/WNL.0b013e31826d5ec0.

12.

Center for Drug Evaluation and Research. Pediatric Research Equity Act. US Food and Drug Administration. November 7, 2019. https://www.fda.gov/drugs/development-resources/pediatric-research-equity-act-prea.

13.

FDA. Rare Pediatric Disease (RPD) Designation and Voucher Programs. US Food and Drug Administration; November 2, 2019. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/rare-pediatric-disease-rpd-designation-and-voucher-programs.

14.

Priority Review to Encourage Treatments for Rare Pediatric Diseases. Authenticated US Government Information. https://www.govinfo.gov/content/pkg/USCODE-2012-title21/pdf/USCODE-2012-title21-chap9-subchapV-partB-sec360ff.pdf.

15.

Office of the Commissioner. Priority Review. US Food and Drug Administration; January 4, 2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.

16.

FDA. Guidance for industry expedited programs for serious conditions—drugs and biologics. 2014. https://www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf.

17.

FDA. Expedited programs for regenerative medicine therapies for serious conditions. 2019. https://www.fda.gov/media/120267/download.

18.

Mitsumoto

Dorsey

Beck

Kieburtz

Griggs

. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol. 2009;66(2):184–190. doi:10.1002/ana.21676.

19.

Drugs@FDA: FDA-approved drugs–Carnexiv. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process.

20.

Idursulfase. DrugBank Online. https://www.drugbank.ca/drugs/DB01271.

21.

Chen

. Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharmaceutica Sinica B. 2020;10(8):1347–1359. doi:10.1016/j.apsb.2020.01.015.

22.

Diseases—DMD—Top level. Muscular Dystrophy Association; April 7, 2020. https://www.mda.org/disease/duchenne-muscular-dystrophy.

23.

Uchitel

Kantor

Smith

Mikati

. Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions. Pediatr Neurol. 2020 Sep;110:5–19. doi: 10.1016/j.pediatrneurol.2020.04.010. Epub 2020 Apr 24. PMID: 32684374.

24.

Fortunato

Farnè

Ferlini

. The DMD gene and therapeutic approaches to restore dystrophin. Neuromuscul Disord. 2021 Oct;31(10):1013–1020. doi: 10.1016/j.nmd.2021.08.004. PMID: 34736624.

25.

Colasante

Lignani

Brusco

, et al. dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice. Mol Ther. 2020;28(1):235–253. doi:10.1016/j.ymthe.2019.08.018.

26.

Ghanavatian

Baclofen. StatPearls. August 22, 2020. https://www.ncbi.nlm.nih.gov/books/NBK526037/.

27.

NIH. BPCA Pediatric drug study: Baclofen for cerebral palsy. Grantome. https://grantome.com/grant/NIH/N01DK63421-7-0-1.

28.

Baclofen (Baclofen Tablets): Uses, dosage, side effects, interactions, warning. RxList; July 8, 2020. https://www.rxlist.com/baclofen-drug.htm.

29.

United Therapeutics. Unituxin for Parents and Caregivers. unituxin.com. https://unituxin.com/caregiver/?gclid=CjwKCAjwm_P5BRAhEiwAwRzSOwlgWJXCrhh6uNl04UBe6CyG0va85VyIEJXwpqTc6Wpqs9hXdmOx9hoC65gQAvD_BwE.

30.

FDA approval for unituxin for pediatric high-risk neuroblastoma. Oncology Times. 2015;37(7):4. doi:10.1097/01.cot.0000464354.02927.67.

31.

North Carolina Consumers Council. FDA approves Xuriden to treat patients with rare metabolic disorder. September 14, 2015. https://www.ncconsumer.org/news-articles/fda-approves-xuriden-to-treat-patients-with-rare-metabolic-disorder.html.

32.

FDA. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. May 24, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease.

33.

FDA. Summary basis for regulatory action: Zolgensma. FDA; May 24, 2019. https://www.fda.gov/media/127961/download.

34.

NIH. Gene replacement therapy clinical trial for participants with spinal muscular atrophy type 1—full text view. July 16, 2020. https://clinicaltrials.gov/ct2/show/NCT03306277.

35.

NIH. A study to assess the efficacy and safety of Nusinersen (ISIS 396443) in infants with spinal muscular atrophy—full text view. July 28, 2017. https://clinicaltrials.gov/ct2/show/NCT02193074.

36.

Gaucher disease types 2 and 3. National Gaucher Foundation; August 17, 2020. https://www.gaucherdisease.org/about-gaucher-disease/what-is/type-2-3/.

37.

Prevail Therapeutics. Our Programs • Prevail: PR001. https://www.prevailtherapeutics.com/programs/.

38.

Rett syndrome. Acadia; September 14, 2020. https://www.acadia-pharm.com/pipeline/rett-syndrome/.

39.

Ovid Therapeutics Inc. Ovid Therapeutics receives FDA rare pediatric disease designation for OV101 for the treatment of Angelman syndrome. GlobeNewswire News Room; June 19, 2020. https://www.globenewswire.com/news-release/2020/06/19/2050675/0/en/Ovid-Therapeutics-Receives-FDA-Rare-Pediatric-Disease-Designation-for-OV101-for-the-Treatment-of-Angelman-Syndrome.html.

40.

Marinus Pharmaceuticals Inc. Marinus Pharmaceuticals completes targeted enrollment in pivotal phase 3 study for CDKL5 deficiency disorder. GlobeNewswire News Room; February 25, 2020. https://www.globenewswire.com/news-release/2020/02/25/1989941/0/en/Marinus-Pharmaceuticals-Completes-Targeted-Enrollment-in-Pivotal-Phase-3-Study-for-CDKL5-Deficiency-Disorder.html.

41.

Meglio

. Ganaxolone receives rare pediatric disease designation for CDD. Neurology Live; August 7, 2020. https://www.neurologylive.com/view/ganaxolone-receives-rare-pediatric-disease-designation-for-cdd.

42.

Uchitel

Alden

Bhutta

, et al. The rights of children for optimal development and nurturing care. Pediatrics. 2019;144(6):e20190 487. doi:10.1542/peds.2019-0487.

43.

Hani

Mikati

. Current and emerging therapies of severe epileptic encephalopathies. Semin Pediatr Neurol. 2016;23(2):180–6. doi:10.1016/j.spen.2016.06.001.

44.

Hunanyan

Kantor

Puranam

Elliott

McCall

Dhindsa

Pagadala

Wallace

Poe

Gunduz

Asokan

Koeberl

ElMallah

Mikati

. Adeno-Associated Virus-Mediated Gene Therapy in the Mashlool, Atp1a3Mashl/+, Mouse Model of Alternating Hemiplegia of Childhood. Hum Gene Ther. 2021 Apr;32(7-8):405–419. doi: 10.1089/hum.2020.191. Epub 2021 Feb 12. PMID: 33577387; PMCID: PMC8182483.

45.

Mesraoua

Deleu

Kullmann

Shetty

Boon

Perucca

Mikati

Asadi-Pooya

. Novel therapies for epilepsy in the pipeline. Epilepsy Behav. 2019 Aug;97:282–290. doi: 10.1016/j.yebeh.2019.04.042. Epub 2019 Jul 6. PMID: 31284159.

46.

Shire. A phase I/II, randomized, safety and ascending dose ranging study of Intrathecal Idursulfase-IT administered in conjunction with intravenous elaprase in pediatric patients with Hunter syndrome and cognitive impairment. clinicaltrials.gov; 2019. https://clinicaltrials.gov/ct2/show/NCT00920647

47.

Selumetinib granted US breakthrough therapy designation in neurofibromatosis type 1. AstraZeneca; April 1, 2019. https://www.astrazeneca.com/media-centre/press-releases/2019/selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1-01042019.html.

48.

National Cancer Institute (NCI). Phase II trial of the MEK1/2 inhibitor Selumetinib (AZD6244 hydrogen sulfate) in adults with neurofibromatosis type 1 (NF1) and Inoperable Plexiform Neurofibromas. clinicaltrials.gov; 2020. https://clinicaltrials.gov/ct2/show/NCT02407405

49.

Hoffman

. Risdiplam gets priority review for spinal muscular atrophy. Neurology Live. https://www.neurologylive.com/view/risdiplam-gets-priority-review-for-spinal-muscular-atrophy.

50.

Hoffmann-La Roche. A two part seamless, open-label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. clinicaltrials.gov; 2021. https://clinicaltrials.gov/ct2/show/NCT02913482.

51.

FDA grants RMAT designation to multistem cell therapy for the treatment of acute respiratory distress syndrome. Athersys, Inc; September 23, 2020. https://www.athersys.com/investors/press-releases/press-release-details/2020/FDA-Grants-RMAT-Designation-to-MultiStem-Cell-Therapy-for-the-Treatment-of-Acute-Respiratory-Distress-Syndrome/default.aspx.

52.

Athersys, Inc. A phase 1/2 study to assess the safety and efficacy of MultiStem® therapy in subjects with acute respiratory distress syndrome. clinicaltrials.gov; 2019. https://clinicaltrials.gov/ct2/show/NCT02611609

53.

FDA. Drug approval package: Vyondys 53 (golodirsen). FDA Drug Approvals and Databases; December 12, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211970Orig1s000Approv.pdf.

54.

Drug Approval Package: Vyondys 53 (golodirsen). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211970Orig1s000TOC.cfm.

55.

Sarepta Therapeutics, Inc. A 2-part, randomized, double-blind, placebo-controlled, dose-titration, safety, tolerability, and pharmacokinetics study (part 1) followed by an open-label efficacy and safety evaluation (part 2) of SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 53 skipping. clinicaltrials.gov; 2020. https://clinicaltrials.gov/ct2/show/NCT02310906.